[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Gilleard O, Goodman A, Cooper M, Davies M, Dunn J: The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol; 2008;6:61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ.
  • BACKGROUND: Debate regarding the benefit of radiotherapy after local excision of ductal carcinoma in situ (DCIS) continues.
  • The Van Nuys Prognostic Index (VNPI) is thought to be a useful aid in deciding which patients are at increased risk of local recurrence and who may benefit from adjuvant radiotherapy (RT).
  • Recently published interim data from the Sloane project has showed that the VNPI score did significantly affect the chances of getting planned radiotherapy in the UK, suggesting that British clinicians may already be using this scoring system to assist in decision making.
  • PATIENTS AND METHODS: A retrospective review was conducted of all patients (n = 215) who underwent breast conserving surgery for DCIS at a single institution between 1997-2006.
  • No patients included in the study received additional radiotherapy or hormonal treatment.
  • Ninety five tumours were high grade (44%) and 84 tumours exhibited comedo necrosis (39%).
  • The VNPI score and the presence of comedo necrosis were the only statistically significant prognostic indicators (P < 0.05).
  • CONCLUSION: This follow-up study of 215 patients with DCIS treated with local excision and observation alone is one of the largest series in which rates of recurrence are unaffected by radiation therapy, hormone manipulation or chemotherapy.
  • It has afforded us the opportunity to assess the prognostic impact of patient and tumour characteristics free of any potentially confounding treatment related influences.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):971-6 [10861308.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2648-53 [17960606.001]
  • [Cites] Lancet. 2003 Jul 12;362(9378):95-102 [12867108.001]
  • [Cites] Oncology (Williston Park). 2003 Nov;17(11):1511-33; discussion 1533-4, 1539, 1542 passim [14682107.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2317-27 [15160334.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):1958-67 [15389481.001]
  • [Cites] Breast Cancer Res Treat. 1992;22(3):207-19 [1391987.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2267-74 [8635094.001]
  • [Cites] N Engl J Med. 1999 May 13;340(19):1455-61 [10320383.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1031-6 [16461781.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):990-8 [16788762.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3381-7 [16801628.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):461-2; author reply 462 [17264349.001]
  • [Cites] J Surg Oncol. 2007 Jun 15;95(8):605-9 [17192948.001]
  • [Cites] J Surg Oncol. 2007 Jun 15;95(8):610-3 [17221862.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):725-9 [17848911.001]
  • [Cites] Clin Breast Cancer. 2007 Aug;7(9):676-81 [17919347.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4):400-18 [11498833.001]
  • (PMID = 18564426.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2459183
  •  go-up   go-down


2. Sauter ER, Ehya H, Mammen A, Klein G: Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy. Br J Cancer; 2001 Dec 14;85(12):1952-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy.
  • We previously demonstrated that abnormal nipple aspirate fluid (NAF) cytology predicted residual breast cancer (RC) and tumour size after excisional biopsy (EB), although normal NAF cytology did not exclude RC.
  • LN metastases provide prognostic information allowing medical and radiation oncologists to determine the need for adjuvant therapy.
  • We hypothesized that pathologic factors known after EB, combined with NAF cytology, would predict with a high degree of accuracy the presence of RC and LN spread.
  • NAF cytology and pathologic parameters: tumour distance from biopsy margins, multifocal and multicentric disease, sub-type of ductal carcinoma in situ (DCIS) or invasive cancer (IC), grade of DCIS or IC, tumour and specimen size, tumour and biopsy cavity location, presence or absence of extensive DCIS, and biopsy scar distance from the nipple were evaluated bivariately and then by logistic regression (LR) for their association with RC and involved LN (> or = 1 (+) LN, useful to determine chemotherapy need, and > or = 4 (+) LN, useful to determine radiation need to the chest and axilla).
  • We propose an algorithm which, if confirmed in a larger study, may allow clinicians to be more selective in their recommendations of re-excision breast biopsy or mastectomy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(7):1222-7 [10584885.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):829-34 [1168727.001]
  • [Cites] Am J Clin Pathol. 1975 Dec;64(6):728-38 [1202937.001]
  • [Cites] J Natl Cancer Inst. 1983 Dec;71(6):1115-21 [6581355.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] Semin Surg Oncol. 1992 May-Jun;8(3):122-8 [1496221.001]
  • [Cites] Arch Surg. 1993 Sep;128(9):1014-8; discussion 1018-20 [8396387.001]
  • [Cites] Ann Surg. 1993 Dec;218(6):729-34 [8257222.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):130-41 [1536131.001]
  • (PMID = 11747339.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 87391
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2364009
  •  go-up   go-down


3. Gupta S, Joshi K, Wig JD, Arora SK: High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor. Indian J Cancer; 2009 Oct-Dec;46(4):303-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor.
  • BACKGROUND: The product of Wilms' tumor suppressor gene (WT1), a nuclear transcription factor, regulates the expression of the insulin-like growth factor (IGF) and transforming growth factor (TGF) systems, both of which are implicated in breast tumorigenesis and are known to facilitate angiogenesis.
  • In the present study, WT1 allelic integrity was examined by Loss of Heterozygosity (LOH) studies in infiltrating breast carcinoma (n=60), ductal carcinoma in situ (DCIS) (n=10) and benign breast disease (n=5) patients, to determine its possible association with tumor progression.
  • TGF-beta1, IGF-II, IGF-1R and angiogenesis (VEGF and Intratumoral micro-vessel density) in breast carcinoma.
  • RESULTS: Six of 22 (27.2%) genetically heterozygous of infiltrating breast carcinoma and 1 of 4 DCIS cases showed loss of one allele at WT1 locus.
  • Histologically, the tumors with LOH at WT1 were Intraductal carcinoma (IDC) and were of grade II and III.
  • There was no correlation in the appearance of LOH at WT1 locus with age, tumor stage, menopausal status, chemotherapy status and lymph node metastasis.
  • The expression of factor IGF-II and its receptor, IGF-1R was significantly higher in carcinoma having LOH at WT1 locus.
  • A positive correlation was observed between the TGF-beta1, VEGF expression and IMD scores in infiltrating carcinoma.
  • CONCLUSIONS: The current study indicates that the high frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in high-graded breast tumors is associated with aggressiveness of the tumor.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Genes, Wilms Tumor
  • [MeSH-minor] Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Humans. Insulin-Like Growth Factor II / biosynthesis. Loss of Heterozygosity. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Receptor, IGF Type 1 / biosynthesis. Transforming Growth Factor beta1 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19749460.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; 0 / Vascular Endothelial Growth Factor A; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


Advertisement
4. Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ: Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ. Cancer Res; 2000 Aug 1;60(15):4284-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ.
  • Adjuvant antiestrogen (AE) therapy has been proposed for all women with ductal carcinoma in situ (DCIS).
  • However, many cases of DCIS are of the high-grade, estrogen receptor (ER)-negative subtype that are unlikely to respond to AE treatment.
  • Hormonal agents work by increasing apoptosis and/or decreasing cell proliferation; therefore, we studied the effect of a pure AE on levels of apoptosis and proliferation in human DCIS xenografts using an in vivo model.
  • Women (n = 23) with mammographic microcalcification suggestive of DCIS were identified at the time of surgery (day 0), a sample of representative tissue was obtained, divided into multiple 2x2x1-mm xenografts, and implanted s.c. into female BALB/c nu/nu mice (eight xenografts/mouse).
  • Fourteen days after implantation, four xenografts were retrieved and mice were randomly divided into one of three treatment groups: (a) insertion of a slow release 2-mg 17beta-estradiol pellet;.
  • After 2 weeks of treatment, the remaining four xenografts were retrieved from each mouse.
  • Retrieved xenografts containing DCIS were assessed for morphological evidence of apoptotic cell death [apoptotic index (AI)] and cell proliferation (by immunohistochemical detection of the Ki67 proliferation antigen LI).
  • Both AI and LI were higher in the day 0 specimens of 16 ER- DCIS lesions compared with 7 ER+ DCIS lesions (mean values, 1.47% versus 0.32% and 20.6% versus 3.1%; both P<0.0001).
  • AI and LI values within ER- DCIS did not differ between xenografts exposed to 17beta-estradiol or AE treatment compared with the controls or pretreatment values (mean AI and LI in estradiol-treated, antiestrogen-treated, and control groups 1.04% versus 0.98% versus 1.29% and 17.2% versus 20.5% versus 17.7% respectively).
  • In contrast, treatment of mice bearing ER+ DCIS xenografts with 17beta-estradiol raised both the AI (1.03% versus 0.40%, P = 0.03) and LI (11.0% versus 5.1%, P = 0.007) compared with controls.
  • AE therapy of ER+ DCIS xenografts did not affect proliferation but resulted in higher apoptosis than in controls (0.9% versus 0.4% respectively, P = 0.04).
  • AE therapy should be reserved for patients with estrogen receptor positive DCIS.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Estradiol / analogs & derivatives. Estrogen Receptor Modulators / pharmacology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Cell Division / drug effects. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Transplantation. Receptors, Estrogen / physiology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10945643.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogen Receptor Modulators; 0 / Receptors, Estrogen; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol
  •  go-up   go-down


5. Bundred NJ, Barnes NL: Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer; 2005 Aug;93 Suppl 1:S10-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
  • Cyclooxygenase-2 (COX-2) is overexpressed in several epithelial tumours, including breast cancer.
  • Cyclooxygenase-2-positive tumours tend to be larger, higher grade, node-positive and HER-2/neu-positive.
  • High COX-2 expression is associated with poor prognosis.
  • Studies of COX-2 inhibitors in breast cancer are underway both alone and in combination with other agents.
  • Preliminary results from combination therapy with celecoxib and exemestane in postmenopausal women with advanced breast cancer showed that the combination increased the time to recurrence.
  • Up to 80% of ductal carcinomas in situ (DCISs) express COX-2, therefore COX-2 inhibition may be of particular use in this situation.
  • As aromatase inhibitors appear particularly effective in patients with HER-2/neu-positive tumours, the combination of aromatase inhibitors and COX-2 inhibitors may be particularly useful in both DCIS and invasive cancer.
  • [MeSH-major] Aromatase Inhibitors / administration & dosage. Breast Neoplasms / drug therapy. Cyclooxygenase Inhibitors / administration & dosage
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols. Apoptosis / drug effects. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Cell Proliferation / drug effects. Female. Humans. Neovascularization, Pathologic / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3808-16 [11559718.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):75-84 [11850210.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):203-12 [11897504.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1676-81 [11912139.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1081-6 [12168077.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5405-7 [12359744.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):574-8 [12592372.001]
  • [Cites] Exp Mol Pathol. 2003 Jun;74(3):282-90 [12782016.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2651-6 [12855643.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4324-31 [14555502.001]
  • [Cites] Lancet Oncol. 2003 Oct;4(10):605-15 [14554238.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(2):117-28 [14572154.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1802-10 [14584060.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91 [14693742.001]
  • [Cites] Histopathology. 2004 Jan;44(1):24-8 [14717665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6 [14688410.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):423-9 [14735188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75 [14751505.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1631-5 [14985703.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):665-73 [15054679.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7 [15217939.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1971-4 [15222049.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):2011-22 [15265936.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] FEBS Lett. 1993 Sep 13;330(2):156-60 [8365485.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3785-9 [7641194.001]
  • [Cites] Biochim Biophys Acta. 1996 Jan 5;1299(1):125-40 [8555245.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] Mol Cell Endocrinol. 1997 Nov 15;134(2):147-56 [9426158.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Int J Biochem Cell Biol. 1999 May;31(5):551-7 [10399316.001]
  • [Cites] Cancer Lett. 1999 Jun 1;140(1-2):27-35 [10403538.001]
  • [Cites] Lab Invest. 1999 Dec;79(12):1469-77 [10616198.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11397-403 [10753955.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1024-8 [10973323.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • (PMID = 16100520.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Cyclooxygenase Inhibitors
  • [Number-of-references] 61
  • [Other-IDs] NLM/ PMC2361689
  •  go-up   go-down


6. Takei H, Kurosumi M, Yoshida T, Ninomiya J, Hagiwara Y, Kamimura M, Hayashi Y, Tozuka K, Suemasu K, Inoue K, Tabei T: Current trends of sentinel lymph node biopsy for breast cancer--a surgeon's perspective. Breast Cancer; 2007;14(4):362-70
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current trends of sentinel lymph node biopsy for breast cancer--a surgeon's perspective.
  • Sentinel lymph node biopsy (SLNB) is standard care for patients with early-stage breast cancer, and axillary lymph node dissection (ALND) is considered unnecessary when sentinel lymph nodes (SLNs) are tumor-free.
  • However, trials concerning the efficacy of ALND in positive SLNB patients in preventing local regional recurrence and improving overall survival compared with no ALND, and also, concerning the effectiveness of ALND compared with axillary radiation therapy (RT), have not yielded clear results.
  • So far SLNB is not acceptable for patients with positive nodes in the axilla at initial diagnosis even if their axillary metastases are down-staged to negative by neoadjuvant chemotherapy.
  • Although basically SLNB does not need to be performed for patients with pure ductal carcinoma in situ (DCIS), it is recommended for patients with an initial diagnosis of DCIS which is large, palpable, high grade, or found in younger patients.
  • Because these types of DCIS have higher incidences of accompanying invasive lesions.
  • SLNB may be acceptable for patients with T3 or T4b tumors, even though SLN identification is lower yet SLN involvement is higher compared with T1 or T2 tumors, and systemic adjuvant therapy is more important for patients with T3 or T4b tumors.
  • SLNB is a bridge to further axillary treatment such as ALND or axillary RT, and which strategy, including no further treatment, is best considered individually based on recurrence risk, treatment responsiveness and use or non-use of systemic therapy.
  • [MeSH-major] Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986801.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 53
  •  go-up   go-down


7. Braud AC, Levy E, Feuilhade F, Otmezguine Y, Calitchi E, Kirova Y, Le Bourgeois JP: Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study. Am J Clin Oncol; 2002 Jun;25(3):303-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study.
  • Achievement of a pathologic complete response after primary chemotherapy in breast cancer can predict long-term outcome.
  • We have investigated a combination of epirubicin, cyclophosphamide, and vinorelbine as neoadjuvant chemotherapy in locally advanced breast cancer (LABC).
  • From January 1997 to May 1999, 30 chemonaive patients were treated (T2 or T3 histologically proven invasive breast carcinoma).
  • Treatment was vinorelbine 25 mg/m2 day 1 and day 3, epirubicin 30 mg/m2/d, days 1 to 3, cyclophosphamide 350 mg/m2/d, days 1 to 3, every 14 days for 4 courses.
  • Median age: 48 years (range: 28-66 years); 26 had ductal invasive carcinoma and 4 lobular invasive carcinoma; median tumor size: 7 cm; median number of induction cycles: four.
  • Twenty-nine patients had surgical treatment.
  • Pathologic response rate was complete response in 32% (no residual tumor), in situ carcinoma: 11%, invasive or unchanged tumor remaining: 57%.
  • Ninety-eight cycles were administered; major toxicities were hematologic: grade IV Hb in 5% and grade IV neutropenia in 60% of cycles.
  • The vinorelbine/epirubicin/cyclophosphamide regimen resulted in a high pathologic complete response rate in LABC with a good tolerance profile, and warrants further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Humans. Middle Aged. Neoadjuvant Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12040294.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; Q6C979R91Y / vinorelbine
  •  go-up   go-down


8. Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS: Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol; 2000 Jan-Feb;7(1):15-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy in ductal carcinoma in situ patients.
  • BACKGROUND: Sentinel lymph node (SLN) mapping is an effective and accurate method of evaluating the regional lymph nodes in breast cancer patients.
  • METHODS: At Moffitt Cancer Center, 87 patients with newly diagnosed pure ductal carcinoma in situ (DCIS) lesions were evaluated by using CK IHC staining of the SLN.
  • Patients with any focus of microinvasive disease, detected on diagnostic breast biopsy by routine H&E, were excluded from this study.
  • DCIS patients, with biopsy-proven in situ tumor by routine H&E stains, underwent intraoperative lymphatic mapping, using a combination of vital blue dye and technetium-labeled sulfur colloid.
  • RESULTS: CK IHC staining was performed on 177 SLNs in 87 DCIS breast cancer patients.
  • Five of the 87 DCIS patients (6%) had positive SLNs.
  • Therefore, routine H&E staining missed microinvasive disease in three of five DCIS patients with positive SLNs.
  • In addition, DCIS patients with occult micrometastatic disease to the SLN underwent a complete axillary lymph node dissection, and the SLNs were the only nodes found to have metastatic disease.
  • Of interest, four of the five node-positive patients had comedo carcinoma associated with the DCIS lesion, and one patient had a large 9.5-cm low grade cribriform and micropapillary type of DCIS.
  • CONCLUSIONS: This study confirms that lymphatic mapping in breast cancer patients with DCIS lesions is a technically feasible and a highly accurate method of staging patients with undetected micrometastatic disease to the regional lymphatic basin.
  • This procedure can be performed with minimal morbidity, because only one or two SLNs, which are at highest risk for containing metastatic disease, are removed.
  • Because most patients with DCIS lesions detected by routine H&E stains do not have regional lymph node metastases, these patients can safely avoid the complications associated with a complete axillary lymph node dissection and systemic chemotherapy.
  • However, DCIS patients with occult micrometastases of the regional lymphatic basin can be staged with higher accuracy and treated in a more selective fashion.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2001 Sep;8(8):617-9 [11569773.001]
  • (PMID = 10674443.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. Zunzunegui RG, Chung MA, Oruwari J, Golding D, Marchant DJ, Cady B: Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease? Arch Surg; 2003 May;138(5):537-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease?
  • HYPOTHESIS: Women with breast cancer who have casting-type microcalcifications associated with multifocal invasion and extensive ductal carcinoma in situ (DCIS) form a subset of patients with a poor prognosis.
  • DESIGN: Women with casting-type microcalcifications, multifocal invasion, and extensive DCIS were identified from our tumor board registry.
  • Mammographic features, tumor characteristics, treatment, and survival rates were evaluated.
  • SETTING: University medical teaching hospital and breast cancer specialty clinic.
  • RESULTS: Of the 984 patients with breast cancer treated at our center, 15 patients were identified who had extensive casting-type calcifications and DCIS.
  • Twelve of these patients also had multifocal invasive breast cancer.
  • All had casting-type microcalcifications occupying more than 1 breast quadrant.
  • All but 1 patient had extensive grade 3 DCIS.
  • Positive axillary lymph nodes were found in 33% of patients, and 75% received adjuvant chemotherapy.
  • Of the 3 patients who had DCIS without invasion, 1 experienced a recurrence with infiltrating ductal carcinoma.
  • CONCLUSIONS: In women with small multifocal breast cancers with extensive casting calcifications and DCIS, the incidence of positive lymph nodes was 33%, with a tendency for poor tumor markers.
  • These women appear to be at substantial risk for systemic disease; lymph node sampling and adjuvant systemic therapy are recommended.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12742959.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Miura H, Taira O, Hiraguri S, Maeda J, Kato H: Recurrent squamous cell carcinoma of the breast with undifferentiated features: report of a case. Surg Today; 2002;32(10):891-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent squamous cell carcinoma of the breast with undifferentiated features: report of a case.
  • Squamous cell carcinoma of the breast is a rare type of cancer, the origin of which is still uncertain.
  • We report a case of squamous cell carcinoma of the breast with a recurrent tumor that showed undifferentiated features.
  • The patient was a 55-year-old woman who originally presented with a left breast mass in the upper outer quadrant.
  • Echography showed a 46 x 29 x 23-mm mass with cavity formation, and aspiration cytology confirmed a diagnosis of squamous cell carcinoma.
  • Pathologically, the tumor was composed of squamous cell carcinoma and noninvasive ductal carcinoma.
  • Despite intensive therapy including chemotherapy (CEF: cyclophosphamide, epirubicin, 5-fluorouracil) and irradiation (50 Gy), the patient died from pulmonary and skin metastases 20 months after her initial operation.
  • The squamous cell carcinoma of the breast in this patient grew rapidly and her prognosis was poor.
  • Immunohistochemical findings indicated the possibility that the squamous cell carcinoma developed from noninvasive ductal carcinoma of the comedo type, and that the undifferentiated cells from the site of recurrence developed from dedifferentiation of the squamous cell carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymph Node Excision. Male. Mastectomy, Modified Radical. Middle Aged. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12376787.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Zujewski JA, Eng-Wong J, O'Shaughnessy J, Venzon D, Chow C, Danforth D, Kohler DR, Cusack G, Riseberg D, Cowan KH: A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer. Breast Cancer Res Treat; 2003 Sep;81(1):41-51
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
  • We conducted a pilot study of dose dense doxorubicin and cyclophosphamide (AC) combination chemotherapy followed by infusional paclitaxel (T) in primary breast cancer to determine its safety and feasibility.
  • Mean overall cycle length was 15.3 days and mean duration of therapy was 92 days.
  • Ninety-five percent of subjects had grade 4 neutropenia and 1 subject had a platelet nadir of < 20,000.
  • Clinical response rate in 10 subjects receiving neoadjuvant therapy was 100% (4 complete response, 6 partial response).
  • Four subjects had a pathologic complete response (three subjects without evidence of malignancy and one subject with ductal carcinoma in situ.
  • ) Administration of dose dense AC followed by infusional paclitaxel in 14-day cycles is feasible and this regimen is active in breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Pilot Projects. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14531496.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Marchesoni D, Driul L, Mozzanega B, Nardelli GB, Parenti A: Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch Gynecol Obstet; 2005 Jan;271(1):62-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.
  • CASE REPORT: In this paper we describe a case of endometrial carcinoma observed in a post-menopausal patient who was treated with tamoxifen for 5 years after a mastectomy for cancer.
  • She came to our department because of vaginal bleeding 2 years after the end of tamoxifen treatment.
  • TREATMENT: She underwent hysteroscopy and a D and C.
  • A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps.
  • OUTCOME: The patient underwent radical hysterectomy, but no residual tumor was found in the uterus or in the tubes, ovary, or pelvic nodes, in spite of its low differentiation grade and high potential aggressiveness, and even though the patient was already symptomatic.
  • [MeSH-major] Adenocarcinoma / chemically induced. Anticarcinogenic Agents / adverse effects. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / surgery. Chemotherapy, Adjuvant. Dilatation and Curettage. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Hysteroscopy. Mastectomy, Radical. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15290168.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


13. Shin SJ, DeLellis RA, Ying L, Rosen PP: Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol; 2000 Sep;24(9):1231-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients.
  • Small cell carcinoma of the breast is an uncommon neoplasm that has been reported rarely in the literature.
  • Nine examples of mammary small cell carcinoma were retrieved from the authors' consultation files and reviewed.
  • Two patients had a previous history of cutaneous malignant melanoma and one had prior lobular carcinoma in situ and atypical duct hyperplasia in the same breast as the small cell carcinoma.
  • Eight patients presented with a mass in the breast; one patient had an axillary tumor.
  • Histologically, the nine tumors had characteristics of small cell carcinoma with high mitotic activity and necrosis.
  • In one instance, this consisted of small cell carcinoma merging with invasive lobular carcinoma.
  • In three cases, small cell carcinoma was present together with invasive, poorly differentiated duct carcinoma; invasive carcinoma with "lobular and gland-forming elements"; and focal squamous differentiation, respectively.
  • An in situ component was seen in seven tumors; five were of the small cell type in ducts and two were of the ductal type with high nuclear grade.
  • Eight underwent an axillary dissection that revealed metastatic carcinoma in four patients.
  • Seven patients received adjuvant chemotherapy and four patients received radiation.
  • Two patients also received tamoxifen treatment.
  • Metastases developed in two patients (22%) with a follow-up period of 11 and 32 months.
  • All patients were alive at last follow up 3 to 35 months after treatment.
  • When compared with published reports of mammary small cell carcinoma, our results show that the prognosis in these patients may not be as poor as previously suggested.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Small Cell / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2001 Jun;25(6):831-2 [11395567.001]
  • (PMID = 10976697.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


14. Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, Chilosi M, Bonetti F: HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol; 2008 Jun;129(6):907-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
  • We evaluated HER-2/neu status in 100 consecutive ductal breast carcinomas by using the Food and Drug Administration (FDA) and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) scoring systems.
  • With the FDA and ASCO/CAP systems, respectively, 3+ cases (n = 23 and 16, respectively) showed high-grade, granular HER-2/neu amplification in 15 (65%) and 14 (88%); low-grade, borderline amplification in 7 (30%) and 1 (6%); and chromosome 17 polysomy without amplification in 1 (4%) and 1 (6%).
  • Concordance between schemes was higher for cases with high-grade, granular HER-2/neu amplification (concordance coefficient, 0.74).
  • Cases with low-grade, borderline HER-2/neu amplification showed poor concordance (concordance coefficient, 0.20).
  • The FDA and ASCO/CAP schemes for HER-2/neu evaluation select patients differently for trastuzumab therapy.
  • Major discordance is present for low-grade, borderline HER-2/neu amplification.
  • FDA low-grade, borderline tumors would be reclassified as without HER-2/neu amplification or as polysomic.
  • The ASCO/CAP scheme has a great concordance coefficient between strong 3+ immunohistochemical cases and cases with high-grade, granular HER-2/neu amplification.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Patient Selection. Practice Guidelines as Topic. Societies, Medical. Trastuzumab. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480007.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


15. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, Stevens D, Brain E, Delaloge S, Mathieu M, Guillot E, Vincent-Salomon A, Cottu PH: Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol; 2009 May 20;27(15_suppl):517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study.
  • : 517 Background: Trials have shown benefit of adjuvant trastuzumab (TZM) for node-positive (N+) or supra-centrimetric HER-2+ breast carcinomas.
  • There are limited data concerning infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • These tumors are being recognized as a high-risk group among all T1a/b tumors.
  • METHODS: Retrospective multicenter series from 2000 to 2008 of infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • Tumors with ≥80% of ductal carcinoma in situ, multifocal and metastatic tumors were excluded.
  • 57% (n = 43) had a sentinel lymph node procedure.
  • 44% (n = 33) had chemotherapy (CT), almost all (31) were associated to TZM.
  • One patient developed myocardial infarction after A resulting in heart failure; 2 had a transient left ventricular ejection fraction decrease below 50% after TZM.
  • Decision of adjuvant CT was associated (all p < 0.05) with hormonal receptors (HR) negative status, Elston-Ellis grade (EE) 2/3 and high mitotic index (MI) while patients with HR+/low MI tumors were rarely treated (p < 0.001).
  • CONCLUSIONS: In our practice, decision of TZM-based therapy for InfraHER-2 N- tumors is associated with high-risk profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Chollet PJ, Dubray P, Durando X, Abrial C, Nayl B, Mouret-Reynier M, Pomel C, Bellière A, Lemery S, Penault-Llorca F: Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT). J Clin Oncol; 2009 May 20;27(15_suppl):e11560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT).
  • : e11560 Background: Trastuzumab plus chemotherapy has become the standard of care for Her-2-positive breast cancer.
  • METHODS: 21 patients (pts) with Her2-positive breast cancer (defined as either immunohistochemical 3+ or fluorescence in situ hybridization-positive) from June 2006 to September 2008 with breast cancer received 3 cycles (c) of FEC 100 ( epirubicin 100 mg/m<sup>2</sup> + 5-fluorouracil and cyclophosphamide 500mg/m<sup>2</sup>) followed by 3 c of D (100mg/m<sup>2</sup>) every 3 weeks +T 2mg/kg weekly or 6mg/kg every 3 weeks (9 weeks of T).
  • pCR was defined according to Chevallier's (Am J Clin Oncol, 1993) as level 1 and 2 and to Sataloff's classification (J Am Coll Surg, 1995) as grade A.
  • A clinical, mammography and ultrasound breast evaluation was performed at baseline, after 3 or 4 c and before surgery.
  • All pts had a ductal carcinoma.
  • 5 pts had inflammatory breast cancer.
  • 1 pts were grade I SBR, 13 grade II SBR, 6 grade III SBR and 1 unspecified.
  • 13 pts (62%) underwent breast-conserving surgery.
  • At the time of the analysis for cardiac evaluation, 8 pts continued to receive adjuvant T. 1 pt was lost for follow-up.
  • CONCLUSIONS: This regimen with only 9 weeks preoperative trastuzumab resulted in a high rate of pCR in Her2-positive tumors, without clinical cardiac events until now.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964071.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Walker RA: The significance of histological determination of HER-2 status in breast cancer. Breast; 2000 Jun;9(3):130-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of histological determination of HER-2 status in breast cancer.
  • Since the identification of the novel transforming gene neu in rat neuroblastomas in 1981, and the subsequent cloning of the human equivalent HER-2, there have been considerable developments concerning the role and value of HER-2 in human breast cancer.
  • Early studies found gene amplification in 20-30% of breast carcinomas, with most studies linking this to poorer survival.
  • Numerous antibodies have been generated against the oncoprotein and in many instances overexpression, as defined by membrane staining of breast cancer cells, correlated with gene amplification.
  • HER-2 can also be detected in high-grade ductal carcinoma in situ.
  • HER-2 status can also aid prediction of response to hormonal and chemotherapy, but the present interest lies in the humanized monoclonal antibody against HER-2 (Herceptin) that has been developed.
  • This is only of value if there is over-expression of HER-2 by a breast cancer, and so a reliable, accurate method of determination of HER-2 status is required.
  • Fluorescent in situ hybridization, which detects gene amplification, is an alternative approach that can be used with fixed embedded tissue but the technique is less widely available.
  • HER-2 is the first oncoprotein involved in breast cancer in which there has been direct translation from the laboratory to the patient.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14731835.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


18. Groves AM, Warren RM, Godward S, Rajan PS: Characterization of pure high-grade DCIS on magnetic resonance imaging using the evolving breast MR lexicon terminology: can it be differentiated from pure invasive disease? Magn Reson Imaging; 2005 Jul;23(6):733-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of pure high-grade DCIS on magnetic resonance imaging using the evolving breast MR lexicon terminology: can it be differentiated from pure invasive disease?
  • Magnetic resonance imaging (MRI) is now a recognized method of imaging the breast.
  • Unfortunately, there is lack of standardization in the MRI terminology used to characterize the appearance of breast lesions.
  • We retrospectively identified cases of pure high-grade ductal carcinoma in situ (DCIS) using the recently introduced breast MRI lexicon and characterized the lesions in order to try and identify features that might distinguish high-grade DCIS from invasive disease.
  • Five-year review of our institution's database revealed 637 patients underwent gadolinium-enhanced breast MRI examination.
  • Twenty patients had histologically proven pure high-grade DCIS.
  • After excluding patients with previous chemotherapy or inadequate MRI examination, 13 patients were analyzed and compared to the 13 most recent cases of pure invasive breast carcinoma.
  • High-grade DCIS cases were significantly more likely to show focal branching pattern (P=.03) and to have an irregular contour (P=.03), compared with invasive disease.
  • Although of marginal statistical significance, DCIS lesions are more likely to have a lower morphological score than invasive carcinoma (P=.06), whilst the latter is more likely to show ring enhancement (P=.07).
  • Use of breast MRI for staging at our institution shows that pure DCIS and pure invasive cancers are both rare entities.
  • Despite the relatively limited numbers, we identified features that would help to differentiate high-grade DCIS from invasive carcinoma on MRI.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / pathology. Carcinoma, Ductal / classification. Carcinoma, Ductal / pathology. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Terminology as Topic
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Great Britain. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Observer Variation. Practice Guidelines as Topic. Reference Standards. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198828.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, Sneige N, Gilcrease MZ: Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol; 2005 Nov;29(11):1456-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer.
  • Metaplastic carcinomas of the breast are a heterogeneous group of neoplasms ranging from tumors with a predominant component of overt carcinoma and focal mesenchymal differentiation to keratin-positive tumors with pure sarcomatoid morphology.
  • Anderson Cancer Center with metaplastic carcinoma of the breast with pure or almost pure sarcomatoid morphology.
  • 1) an invasive carcinomatous component identifiable on hematoxylin and eosin stains comprising less than 5% of the invasive tumor; or 2) associated ductal carcinoma in situ; or 3) immunohistochemical expression of keratin in the sarcomatoid areas.
  • Patients with low-grade fibromatosis-like metaplastic tumors and those who received neoadjuvant chemotherapy were excluded.
  • Ten patients experienced local relapse, including 7 of 11 patients treated with breast-conserving surgery, and 9 developed distant metastases, most frequently to the lungs.
  • In addition to systemic treatment, early aggressive local therapy is recommended, as these patients have a high rate of local relapse.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Aug;30(8):1052-3; author reply 1053-5 [16861980.001]
  • (PMID = 16224212.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Vaughan A, Dietz JR, Aft R, Gillanders WE, Eberlein TJ, Freer P, Margenthaler JA: Scientific Presentation Award. Patterns of local breast cancer recurrence after skin-sparing mastectomy and immediate breast reconstruction. Am J Surg; 2007 Oct;194(4):438-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scientific Presentation Award. Patterns of local breast cancer recurrence after skin-sparing mastectomy and immediate breast reconstruction.
  • Nine developed in the quadrant of the corresponding primary tumor.
  • There were no significant differences between patients who recurred and those who did not with respect to tumor size/stage, margin status, estrogen receptor/progesterone receptor/Her2neu status, lymph node metastases, or radiation therapy (P > .05).
  • Patients with grade 3 invasive tumors or high-grade ductal carcinoma in situ were more likely to recur than patients with grade 1 or 2 invasive tumors or low- or intermediate-grade ductal carcinoma in situ (P = .0035).
  • Recurrences occur most commonly in the same quadrant as the primary tumor and treatment approaches include surgery, chemotherapy, and radiation therapy.
  • [MeSH-major] Breast Neoplasms / surgery. Mammaplasty. Mastectomy / methods. Neoplasm Recurrence, Local / epidemiology. Skin
  • [MeSH-minor] Adult. Female. Humans. Retrospective Studies. Time Factors


21. Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, Sarrió D, Martín-Guijarro Mdel C, Hernandez L, Palacios J: Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol; 2007 Apr;31(4):501-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
  • It is not clear whether invasive breast carcinomas with medullary features (IBCMFs, atypical medullary carcinomas) constitute a specific phenotype of breast cancer that is of biologic significance.
  • We studied the immunohistochemical expression of 15 markers in tissue microarrays containing samples from 35 IBCMFs and 39 grade 3 invasive ductal carcinomas (IDCG3s) of no special type.
  • In addition, we analyzed EGFR, C-MYC, and CCNE gene amplification by fluorescence in situ hybridization, because the expression of these genes is known to be associated with the basal-like phenotype.
  • The identification of IBCMF as an independent group of tumors could be of clinical significance, given the high incidence of cases with a basal-like phenotype, which is a group of tumors with different prognosis and chemotherapy response from those of IDCG3s of no special type.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Medullary / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cyclin E / genetics. Female. Gene Amplification. Genes, erbB-1. Genes, myc. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Tissue Array Analysis


22. Bonadona V, Dussart-Moser S, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, Brémond A, Treilleux I, Martin A, Romestaing P, Raudrant D, Rudigoz RC, Lenoir GM, Lasset C: Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat; 2007 Jan;101(2):233-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
  • PURPOSE: The debate concerning poorer survival for patients with breast cancer (BC) carrying a BRCA1 germline mutation is unresolved, and requires additional data from population-based studies.
  • RESULTS: As compared to sporadic tumours, BRCA1/2 tumours showed higher grade (P = 0.02), fewer ductal carcinoma in situ (P = 0.02), more frequent medullary histology (P = 0.02), more frequent negative oestrogen and progesterone receptors (P = 0.001 each).
  • 76% of BRCA1/2 carriers received chemotherapy.
  • The high rate of BRCA1 carriers who received chemotherapy for their BC should question the positive impact of this treatment, as suggested by preclinical studies showing increased chemosensitivity of BRCA1-associated tumours.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / mortality. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061047.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Jhingran A, Kim JS, Buchholz TA, Katz A, Strom EA, Hunt KK, Sneige N, McNeese MD: Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: The University of Texas M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys; 2002 Nov 1;54(3):804-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: The University of Texas M. D. Anderson Cancer Center experience.
  • PURPOSE: To analyze the long-term outcome of breast conservation therapy in patients with ductal carcinoma in situ (DCIS) in a single institution and to analyze the prognostic importance, if any, of young patient age.
  • METHODS AND MATERIALS: The hospital records of 150 patients with DCIS treated with surgical excision and radiotherapy at our institution between 1980 and 1997 were retrospectively reviewed.
  • Local recurrence correlated with nuclear grade (p = 0.002) but was not associated with patient age at diagnosis (<40 years vs. >or=40 years, p = 0.39).
  • In all cases of local recurrence, patients underwent surgery with or without chemotherapy, and disease control was achieved.
  • CONCLUSION: The results of this study demonstrate high rates of long-term overall survival, disease-specific survival, and local control in patients with DCIS of the breast treated conservatively with segmental mastectomy and radiotherapy.
  • Continued studies in young patients treated with breast conservative therapy for DCIS are needed.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Middle Aged. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377332.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


24. Prasad ML, Osborne MP, Giri DD, Hoda SA: Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol; 2000 Mar;24(3):422-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases.
  • Clinicopathologic data on microinvasive carcinoma of the breast (MICB) as defined by the 1997 TNM criteria (T1mic < or = 1 mm) is scarce.
  • MICB was ductal in 18 patients, including one tubular carcinoma, and was lobular in three patients.
  • The accompanying duct carcinoma in situ had high-grade nuclei and necrosis in 16 of 18 patients (89%), 13 of which (72%) were comedo-type.
  • Eleven patients underwent mastectomy, nine received radiation therapy, one received chemotherapy, and two underwent lumpectomy only.
  • One patient had a chest wall recurrence of infiltrating duct carcinoma and another recurred with duct carcinoma in situ.
  • [MeSH-major] Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10716157.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. Hird RB, Chang A, Cimmino V, Diehl K, Sabel M, Kleer C, Helvie M, Schott A, Young J, Hayes D, Newman L: Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer; 2006 May 15;106(10):2113-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
  • BACKGROUND: Recent data have demonstrated that benefit from adjuvant tamoxifen therapy for patients with ductal carcinoma in situ (DCIS) is limited to estrogen receptor (ER)-positive lesions.
  • The objective of the current study was to correlate clinicopathologic features of DCIS with ER expression and the impact of this information on tamoxifen counseling.
  • METHODS: Women with DCIS who were treated from 2001 to 2004 were evaluated.
  • The mean DCIS size was 0.98 cm.
  • All Grade 1 and 2 DCIS lesions were ER-positive, compared with 54% of high-grade lesions (P<.001); no other clinicopathologic feature significantly predicted ER status.
  • In the pre-ER staining period, surgical treatment and grade were associated with offering tamoxifen (75% of patients who underwent breast conservation vs. 40% of patients who underwent mastectomy; P = .03; 78% of patients with Grade 1 or 2 lesions vs. 45% of patients with Grade 3 lesions; P = .04).
  • Approximately 66% of patients who were offered tamoxifen agreed to treatment (approximately 33% of the total DCIS study sample).
  • CONCLUSIONS: Seventy-five percent of DCIS lesions were ER-positive.
  • ER staining significantly influenced the likelihood that clinicians would offer tamoxifen to patients with DCIS, but it had no impact on whether patients accepted treatment.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Receptors, Estrogen / analysis. Tamoxifen / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Mastectomy / methods. Middle Aged. Neoplasm Staging. Patient Compliance. Probability. Registries. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society
  • (PMID = 16596655.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


26. Amersi F, Hansen NM: The benefits and limitations of sentinel lymph node biopsy. Curr Treat Options Oncol; 2006 Mar;7(2):141-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The status of the axilla is the single most important prognostic indicator of overall survival in patients with breast cancer.
  • The number of lymph nodes, although prognostic, no longer impacts treatment options.
  • Sentinel lymph node (SLN) mapping and dissection is a more sensitive and accurate technique for nodal evaluation and has been applied to staging of axillary lymph nodes in patients with breast cancer, providing prognostic information, with less surgical morbidity than with axillary lymph node dissection (ALND).
  • When analyzed by an experienced pathologist with serial sectioning and immunohistochemical evaluation, SLN is the most accurate detection tool used in staging of breast cancer.
  • In addition, this technique may also be therapeutic because in most patients, the SLN is the only positive axillary node.
  • SLN biopsy is justified in women with ductal carcinoma in situ who have a high risk of invasive carcinoma, such as those with large tumors, a mass, or high-grade lesions.
  • SLN biopsy is performed in the setting of neoadjuvant chemotherapy and demonstrates accurate evaluation of the axilla in 90% of the cases.
  • Women with locally advanced breast cancer may derive great benefit from a minimally invasive approach to the axilla because the extent of nodal involvement is unlikely to change further treatment.
  • For clinically palpable nodes, ALND should be performed for therapeutic and local control.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / secondary. Lymph Nodes / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Female. Humans. Lymphatic Metastasis. Mastectomy. Neoadjuvant Therapy. Pregnancy. Pregnancy Complications, Neoplastic / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Commun. 2001 Apr;22(4):361-6 [11338045.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2187-94 [11147588.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):272-7 [11923134.001]
  • [Cites] Surgery. 2000 Jul;128(1):6-12 [10876178.001]
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):283-302 [15916855.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):354-8 [15725804.001]
  • [Cites] CA Cancer J Clin. 2000 Sep-Oct;50(5):279-91 [11075238.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2345-50 [9196149.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):118-20 [12633552.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12 (11):895-9 [16195833.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9):688-92 [11597008.001]
  • [Cites] J Surg Res. 1999 Jun 15;84(2):138-42 [10357910.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):101-9 [10458223.001]
  • [Cites] Ann Surg. 2003 May;237(5):732-8; discussion 738-9 [12724640.001]
  • [Cites] Oncologist. 2005 Apr;10(4):242-9 [15821244.001]
  • [Cites] Br J Surg. 1986 Jul;73(7):580-4 [3730795.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):243-7 [11923130.001]
  • [Cites] Cancer J Sci Am. 1997 Nov-Dec;3(6):336-40 [9403045.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1137-46 [15674853.001]
  • [Cites] Lancet. 1997 Jun 28;349(9069):1864-7 [9217757.001]
  • [Cites] Ann Oncol. 1999 Jan;10(1):47-52 [10076721.001]
  • [Cites] J Natl Cancer Inst Monogr. 1997;(22):151-6 [9709292.001]
  • [Cites] Am J Surg. 2000 Oct;180(4):274-7 [11113434.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2540-5 [10861431.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):81-9 [10862199.001]
  • [Cites] J Surg Oncol. 2003 Oct;84(2):63-7 [14502778.001]
  • [Cites] J Am Coll Surg. 1998 Apr;186(4):423-7 [9544956.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] N Engl J Med. 2002 Oct 17;347(16):1233-41 [12393820.001]
  • [Cites] Pathol Oncol Res. 1998;4(4):301-3 [9887361.001]
  • [Cites] Eur J Cancer. 1994;30A(5):645-52 [8080680.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3C):2167-71 [9703779.001]
  • [Cites] Am J Surg. 2001 Oct;182(4):407-10 [11720681.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):235-42 [11923129.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):931-42 [12875603.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] N Engl J Med. 2002 Oct 17;347(16):1227-32 [12393819.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):159-63 [15692758.001]
  • [Cites] Ann Surg. 1995 Sep;222(3):394-9; discussion 399-401 [7677468.001]
  • [Cites] Breast J. 2004 Nov-Dec;10 (6):492-5 [15569204.001]
  • [Cites] Am J Surg. 2001 Oct;182(4):312-5 [11720661.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):1-7 [10862188.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54 [12381707.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):229-35 [15720997.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):77-84 [9887158.001]
  • [Cites] Ann Surg. 2000 May;231(5):724-31 [10767794.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1368-77 [11745212.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):445-9 [8233285.001]
  • [Cites] CA Cancer J Clin. 2002 Sep-Oct;52(5):277-300 [12363326.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1080-4 [11571718.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2560-6 [10893287.001]
  • [Cites] BMJ. 2005 Oct 8;331(7520):789-90 [16210257.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):261-9 [3276824.001]
  • [Cites] Am J Surg. 2002 Jan;183(1):23-7 [11869698.001]
  • [Cites] J Am Coll Surg. 2005 Jan;200(1):10-4 [15631914.001]
  • [Cites] Surg Oncol. 1993 Dec;2(6):335-9; discussion 340 [8130940.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):546-53 [12904519.001]
  • [Cites] N Engl J Med. 1998 Oct 1 ;339(14 ):941-6 [9753708.001]
  • [Cites] Eur J Surg Oncol. 2003 May;29(4):341-50 [12711287.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):450-4 [10458682.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17 ):1297-306 [11535704.001]
  • [Cites] Clin Breast Cancer. 2004 Aug;5(3):235-8 [15335458.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):745-53 [12374657.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3480-6 [11032588.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):563-6 [16164920.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401 [8092905.001]
  • [Cites] Cancer Clin Trials. 1981 Fall;4(3):229-36 [7026073.001]
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):21-7 [10674444.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):232-6 [15780556.001]
  • (PMID = 16455025.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


27. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, Merajver SD: RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat; 2005 Sep;93(2):101-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
  • BACKGROUND: There is a need for reliable predictors of breast cancer aggressiveness that will further refine the staging classification and help guide the implementation of novel therapies.
  • We have identified RhoC as being nearly always overexpressed in the most aggressive form of breast cancer, inflammatory breast cancer (IBC); in subsequent work we identified RhoC to be a promising marker of aggressive behavior in breast cancers less than 1 cm in diameter.
  • We hypothesized that RhoC expression would identify aggressive, non-IBC tumors breast cancer patients at any stage with worse outcomes defined as recurrence and/or metastasis.
  • METHODS: We constructed four high-density tissue microarrays (TMAs) using 801 tissue cores from 280 patients.
  • These tissues represent a wide range of normal breast and breast disease, including intraductal hyperplasia, ductal carcinoma in situ (DCIS), invasive carcinomas, and distant metastases.
  • The TMAs were immunostained using a polyclonal anti-RhoC antibody developed in our laboratory.
  • RESULTS: RhoC expression increases with breast cancer progression.
  • All samples of normal breast epithelium had negative to weak staining, whereas staining intensity increased in hyperplasia, DCIS, invasive carcinoma, and metastases (Kruskal-Wallis p < 0.001).
  • In patients with invasive carcinoma, high RhoC expression was associated with features of aggressive behavior including high histologic grade, positive lymph nodes, and negative hormonal receptor status.
  • High RhoC expression was a predictor of overall survival in patients with breast cancer (log rank test, p = 0.002) and was associated with 100% increase in the risk of death as compared to patients with low RhoC expression.
  • Importantly, high RhoC was an independent predictor of poor response to doxorubicin-based chemotherapy with a hazard ratio of 3.1 and a 95% CI of 1.2-7.7 (p = 0.02).
  • CONCLUSION: RhoC expression increases with breast cancer progression and RhoC protein level in tumor tissue is strongly associated with biologically aggressive invasive carcinomas of the breast.
  • RhoC expression, if validated, may identify patients who are less likely benefit from doxorubicin therapy and suggests RhoC overexpression as a new target for intervention.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. rho GTP-Binding Proteins / analysis
  • [MeSH-minor] Disease Progression. Female. Humans. Immunohistochemistry / methods. Prognosis. Reproducibility of Results. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187229.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P50-CADE97258; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / K08 CA 090876; United States / NCI NIH HHS / CA / R01CA10746; United States / NCI NIH HHS / CA / R01CA77612
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RHOC protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


28. Carter MR, Hornick JL, Lester S, Fletcher CD: Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol; 2006 Mar;30(3):300-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases.
  • Spindle cell (sarcomatoid) carcinoma of the breast is a rare variant of breast cancer that has been classified under the broad rubric of metaplastic carcinoma.
  • Because the term "metaplastic carcinoma" comprises a heterogeneous group of tumors, it has been difficult to reliably predict biologic potential or to determine optimal therapy.
  • To better characterize the spindle cell subset of metaplastic breast carcinomas, we reviewed 29 cases.
  • Treatment was by excision and/or mastectomy with axillary node evaluation in most cases, often combined with postoperative radiation and/or chemotherapy.
  • All cases were clinically of breast origin, showed >or=80% spindled/sarcomatoid morphology, and demonstrated keratin positivity and/or close association with ductal carcinoma in situ.
  • Twenty-seven cases exhibited pure spindled or sarcomatoid morphology of variable appearance and nuclear grade, whereas 2 contained high-grade invasive ductal carcinoma comprising <or=20% of the tumor mass.
  • Two cases exhibited heterologous elements (1 rhabdomyosarcoma and 1 with both chondrosarcoma and osteosarcoma) and 4 were associated with ductal carcinoma in situ.
  • Of 20 cases in which axillary nodes were biopsied, definitive nodal metastases were identified in only 1 (5%), and this was in a case with a significant component of invasive ductal carcinoma.
  • Three patients developed local recurrences.
  • Based on this series, spindle cell/sarcomatoid carcinoma of the breast is a highly aggressive neoplasm with a high rate of extranodal metastases.
  • Purely spindled/sarcomatoid tumors have a significantly lower rate of nodal metastases than conventional ductal and lobular breast carcinomas.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Sarcoma / metabolism. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2007 Feb;31(2):326-7; author reply 327 [17255781.001]
  • (PMID = 16538049.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Wasserberg N, Morgenstern S, Schachter J, Fenig E, Lelcuk S, Gutman H: Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component. Arch Surg; 2002 Nov;137(11):1249-52
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component.
  • HYPOTHESIS: Clinical and pathological variables may be predictors of axillary dissemination in T1mic and T1a breast carcinoma.
  • PATIENTS: All patients diagnosed as having ductal carcinoma in situ (DCIS) with microinvasion between January 1, 1988, and December 30, 1998.
  • Modified radical mastectomy was performed in 29 patients (18 with T1mic and 11 with T1a) and breast-preserving surgery in 28 (19 with T1mic and 9 with T1a).
  • Forty-seven patients received adjuvant therapy (radiotherapy alone, or with hormones or chemotherapy).
  • One patient was unavailable for follow-up, another died of disseminated disease, and a third developed contralateral primary carcinoma.
  • Comedo DCIS (P<.03) and the number of DCIS-involved ducts (P<.002) in the T1mic group, and nuclear grade 3 (P<.001) in both groups, were independent significant predictors of axillary metastases.
  • CONCLUSIONS: The significant rate of axillary metastases in T1a and T1mic breast tumors makes axillary staging a must.
  • High nuclear grade, comedo DCIS, and high number of DCIS-involved ducts may predict axillary metastasis and should be considered when axillary dissection is done selectively.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Lymph Node Excision. Lymphatic Metastasis / diagnosis

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413311.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement